0001104659-22-123365.txt : 20221130
0001104659-22-123365.hdr.sgml : 20221130
20221130203301
ACCESSION NUMBER: 0001104659-22-123365
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221128
FILED AS OF DATE: 20221130
DATE AS OF CHANGE: 20221130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelly Scott A.
CENTRAL INDEX KEY: 0001703394
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-49908
FILM NUMBER: 221436955
MAIL ADDRESS:
STREET 1: C/O CYTODYN INC.
STREET 2: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytoDyn Inc.
CENTRAL INDEX KEY: 0001175680
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 753056237
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0531
BUSINESS ADDRESS:
STREET 1: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
BUSINESS PHONE: 360-980-8524
MAIL ADDRESS:
STREET 1: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
FORMER COMPANY:
FORMER CONFORMED NAME: CYTODYN INC
DATE OF NAME CHANGE: 20031114
FORMER COMPANY:
FORMER CONFORMED NAME: REXRAY CORP
DATE OF NAME CHANGE: 20020617
4
1
tm2231600-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-11-28
0
0001175680
CytoDyn Inc.
CYDY
0001703394
Kelly Scott A.
1111 MAIN STREET, SUITE 660
VANCOUVER
WA
98660
0
1
0
0
CMO
Common Stock
2022-11-30
4
A
0
16927
0.00
A
2184037
D
Common Stock
782408
I
By Spouse
Non-qualified stock option (right to buy)
0.35
2022-11-28
4
A
0
2315439
0
A
2032-11-28
Common Stock
2315439
2315439
D
Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.
/s/ Antonio Migliarese, Attorney-In-Fact
2022-11-30